SCHEMBL319980

SCHEMBL319980

CCCCCCCC(CO)C(=O)OCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 2/20 0.53
CA2 P00918 2/20 0.48
LMNA P02545 2/20 0.47
ZDHHC7 Q9NXF8 1/20 0.46
CA1 P00915 1/20 0.44
GRIK1 P39086 2/20 0.43
GRIK2 Q13002 2/20 0.43
GPR84 Q9NQS5 3/20 0.42
FFAR1 O14842 1/20 0.42
KDM4E B2RXH2 1/20 0.42
DUSP3 P51452 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPT P10636 2/20 0.42
MAPK1 P28482 1/20 0.42
LCK P06239 1/20 0.41
PPARD Q03181 1/20 0.41
ZDHHC20 Q5W0Z9 1/20 0.41
ZDHHC2 Q9UIJ5 1/20 0.41
SLC1A2 P43004 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL277442 1.00 CPB2 (0.53) CPB2CA2LMNAZDHHC7CA1
Methyl Alcohol SCHEMBL7668985 0.98 CPB2 (0.51) CPB2CA2LMNAZDHHC7CA1
Ammonia Solution, Strong SCHEMBL5121318 0.98 CPB2 (0.51) CPB2CA2LMNAZDHHC7CA1
SCHEMBL3845206 0.98 CPB2 (0.50) CPB2CA2LMNAZDHHC7CA1
Acetic Acid SCHEMBL3260364 0.95 CPB2 (0.49) CPB2CA2LMNAZDHHC7CA1
Ethyl Acetate SCHEMBL1279632 0.93 CPB2 (0.47) CPB2CA2LMNAZDHHC7CA1
Ethyl Acetate SCHEMBL5064725 0.93 CPB2 (0.47) CPB2CA2LMNAZDHHC7CA1
SCHEMBL3176263 0.92 CA2 (0.52) CPB2CA2CA1KDM4EDUSP3
Ethyl Acetate SCHEMBL17005456 0.90 CPB2 (0.45) CPB2CA2LMNAZDHHC7GRIK1
Ethyl Acetate SCHEMBL17699277 0.90 CPB2 (0.45) CPB2CA2LMNAZDHHC7GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117624307-A Process for preparing cyclic organic compounds 中外制药株式会社 2024-03-01 CN disclosed
EP-4271316-A1 NOVEL ANTIMICROBIAL COMPOSITIONS AND ARTICLES MADE THEREFROM 3M Innovative Properties Company (US) 2023-11-08 EP disclosed
US-11807664-B2 Method for producing cyclic organic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-07 US disclosed
CN-116635017-A Novel antimicrobial compositions and articles made therefrom 3M创新有限公司 2023-08-22 CN disclosed
WO-2022144664-A1 NOVEL ANTIMICROBIAL COMPOSITIONS AND ARTICLES MADE THEREFROM 3M INNOVATIVE PROPERTIES COMPANY (US) 2022-07-07 WO disclosed
US-20210147475-A1 METHOD FOR PRODUCING CYCLIC ORGANIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-05-20 US disclosed
EP-3623378-A1 METHOD FOR PRODUCING CYCLIC ORGANIC COMPOUND Chugai Seiyaku Kabushiki Kaisha (JP) 2020-03-18 EP disclosed
CN-110799523-A Process for preparing cyclic organic compounds 中外制药株式会社 2020-02-14 CN disclosed
EP-2558446-B1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC IMMUNE SA (CH) 2019-06-12 EP disclosed
CN-105008341-B Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals 赛诺菲 2017-10-24 CN disclosed
US-6391882-B1 PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS H. LUNDBECK A/S (DK) 2002-05-21 US disclosed
EP-1089997-A1 4,5,6 AND 7-INDOLE AND INDOLINE DERIVATIVES, THEIR PREPARATION AND USE H.Lundbeck A/S (DK) 2001-04-11 EP disclosed
CN-1259119-A Substituted 3, 3-diamino-2-propenenitriles, their preparation and use NOVO NORDISK AS (DK) 2000-07-05 CN disclosed
EP-1007523-A1 INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2000-06-14 EP disclosed
EP-0994107-A1 5-Arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds H. LUNDBECK A/S (DK) 2000-04-19 EP disclosed
WO-1999067237-A1 4,5,6 AND 7-INDOLE AND INDOLINE DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 1999-12-29 WO disclosed
US-5955548-A POTASSIUM CHANNEL MODULATORS NOVO NORDISK A/S (DK) 1999-09-21 US disclosed
WO-1999005140-A1 INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 1999-02-04 WO disclosed
EP-0726896-A1 5-ARYLISOXAZOL-4-YL-SUBSTITUTED 2-AMINO CARBOXYLIC ACID COMPOUNDS H. LUNDBECK A/S (DK) 1996-08-21 EP disclosed
WO-1995012587-A1 5-ARYLISOXAZOL-4-YL-SUBSTITUTED 2-AMINO CARBOXYLIC ACID COMPOUNDS H. LUNDBECK A/S (DK) 1995-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210147475-A1 METHOD FOR PRODUCING CYCLIC ORGANIC COMPOUND SCTR, CTRC, DCXR CPB2 1106/4885CA2 1880/4885LMNA 4106/4885
US-11807664-B2 Method for producing cyclic organic compound SCTR, CTRC, DCXR CPB2 1106/4885CA2 1880/4885LMNA 4106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.